Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New era for treatment in differentiated thyroid cancer.
Haraldsdottir S, Shah MH. Haraldsdottir S, et al. Among authors: shah mh. Lancet. 2014 Jul 26;384(9940):286-8. doi: 10.1016/S0140-6736(14)60663-2. Epub 2014 Apr 24. Lancet. 2014. PMID: 24768111 No abstract available.
Phase II trial of sorafenib in metastatic thyroid cancer.
Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Kloos RT, et al. Among authors: shah mh. J Clin Oncol. 2009 Apr 1;27(10):1675-84. doi: 10.1200/JCO.2008.18.2717. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255327 Free PMC article. Clinical Trial.
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Lam ET, et al. Among authors: shah mh. J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368568 Free PMC article. Clinical Trial.
Role of BRAF in thyroid oncogenesis.
Caronia LM, Phay JE, Shah MH. Caronia LM, et al. Among authors: shah mh. Clin Cancer Res. 2011 Dec 15;17(24):7511-7. doi: 10.1158/1078-0432.CCR-11-1155. Epub 2011 Sep 7. Clin Cancer Res. 2011. PMID: 21900390 Review.
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. Cabanillas ME, et al. Among authors: shah mh. Cancer. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24. Cancer. 2015. PMID: 25913680 Free PMC article. Clinical Trial.
Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.
Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B. Burkart J, et al. Among authors: shah mh. J Natl Compr Canc Netw. 2018 Sep;16(9):1035-1040. doi: 10.6004/jnccn.2018.7043. J Natl Compr Canc Netw. 2018. PMID: 30181415
Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies.
Haraldsdottir S, Janku F, Poi M, Timmers C, Geyer S, Schaaf LJ, Sexton J, Wei L, Thurmond J, Velez-Bravo V, Stepanek VM, Bertino EM, Kendra K, Mortazavi A, Subbiah V, Phelps M, Shah MH. Haraldsdottir S, et al. Among authors: shah mh. JCO Precis Oncol. 2018 Nov;2:1-19. doi: 10.1200/PO.17.00247. JCO Precis Oncol. 2018. PMID: 35135123
345 results